TLR2
- Known as:
- TLR2
- Catalog number:
- 000136A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- TLR2
Related genes to: TLR2
- Gene:
- TLR2 NIH gene
- Name:
- toll like receptor 2
- Previous symbol:
- -
- Synonyms:
- TIL4, CD282
- Chromosome:
- 4q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-25
- Date modifiied:
- 2016-10-25
Related products to: TLR2
Related articles to: TLR2
- - Source: PubMed
Luo HaodangZeng QianruiXie NaZhang ChiLiu ChangChen ShutongYan CaihongLi ChunWu HaiyingHe JunZeng YanhuaYou Xiaoxing - This review summarizes the current understanding of chitosan as a chemically tunable vaccine adjuvant, with a particular focus on the relationships between material determinants, innate immune activation, and translational formulation design. From a materials science perspective, we discuss how molecular weight, charge density, and composite construction with organic or inorganic components shape the physicochemical behavior of chitosan-based systems. It then summarizes, from an immunological perspective, the pathways through which chitosan-based adjuvants activate immune responses-including the cGAS-STING pathway, the NLRP3 inflammasome, and TLR2/TLR4-and how they balance humoral and cellular immunity. Finally, we also analyze the context-dependent applicability of various chitosan-based formulations, such as nanoparticles and hydrogels, along with the design rationale for synergistic "chitosan + X" (e.g, TLR agonists, cytokines) adjuvant systems. We highlight key translational challenges, including poor solubility at neutral pH, structural heterogeneity, endotoxin and impurity control, batch-to-batch reproducibility, and chemistry, manufacturing, and controls (CMC) requirements. Collectively, this review provides a theoretical framework for rational formulation selection, critical quality attribute standardization, and the prioritization of clinically feasible chitosan-based adjuvant platforms. - Source: PubMed
Publication date: 2026/08/07
Li ZiyiZhang XiuliLiu NanXia NingshaoGu YingLi Shaowei - Pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) remain lethal malignancies with limited therapeutic options, highlighting an urgent need for more effective treatments. Integrin αvβ6 (ITGB6) is a receptor preferentially expressed in specific types of tumors, such as PDAC and LUAD, and represents a promising yet largely untapped target for cellular immunotherapy. We aimed to develop and preclinically validate a novel chimeric antigen receptor T-cell (CAR-T) therapy targeting ITGB6 for these aggressive solid tumors. A third-generation anti-ITGB6 CAR was designed and constructed, incorporating both CD28 and TLR2 co-stimulatory domains. TLR2 signaling enhances T-cell expansion, cytokine production, and infiltration into solid tumor. The potency and specificity of anti-ITGB6 CAR-T cells were assessed against a panel of ITGB6-positive PDAC and LUAD cell lines, patient-derived organoids (PDOs), orthotopic models, and patient-derived xenograft (PDX) models. Anti-ITGB6 CAR-T cells demonstrated potent cytotoxicity against ITGB6-positive PDAC and LUAD models in vitro, effectively targeting both cell lines and PDOs. In murine xenograft models, a single dose of anti-ITGB6 CAR-T cells induced significant tumor suppression and prolonged survival, with no evidence of on-target/off-tumor toxicity was observed. Our findings provide compelling preclinical proof-of-concept for anti-ITGB6 CAR-T therapy as a potent and safe investigational strategy against ITGB6-positive solid tumors, supporting its clinical translation for patients with PDAC and LUAD. - Source: PubMed
Publication date: 2026/08/13
Shi LingchaoQin LeSun ShuxinYin KaiJia HengZheng YongfangHuang YunlinCarson GeorgiaWu QitingLong YouguoWu ZhipingShi Xing-YuanZheng RunhuiQin DajiangFeng LiqiangWu LinpingHe JunChen JiekaiYao YaoLi Peng - Rosacea is a chronic inflammatory skin condition. Excessive LL-37 is produced when serine protease kallikrein-5 (KLK5) is hyperactivated, contributing to the inflammatory response in rosacea. Thus, inhibition of KLK5 has the potential to attenuate inflammation in this condition. Reports suggest that specnuezhenide (Spe), an isomer of oleanolic acid, is effective as an anti-inflammatory agent for the treatment of inflammatory diseases. However, little is known about the role of Spe and its mechanisms in alleviating rosacea. - Source: PubMed
Publication date: 2026/07/29
Xu JingangLi XinyuChen ManyuDi ShahongZhang YaoXu YueyeXu BoyaGuo JunjieXu JingyunLi YuanyuanZhao Jinhong - We explored the potential functions of differentially expressed miRNAs, mRNAs, lncRNAs, and circRNAs identified in the ovaries of gilts with normal estrus (NE) and follicular cyst-associated anestrus (AE), as well as their putative competing endogenous RNA (ceRNA) regulatory networks. Ovarian morphology was assessed via ultrasonography, and serum concentrations of Follicle-stimulating hormone (FSH), (Estradiol) E2, and Progesterone(P4) were measured. Ovarian tissues were harvested after slaughter for whole-transcriptome sequencing. Bioinformatic tools were used to screen differentially expressed RNAs(DERNAs) between NE and AE gilts. We further predicted target interactions among these transcripts, conducted functional enrichment analysis on target genes, and constructed candidate ceRNA regulatory networks potentially associated with gilt estrus. Phenotypic verification confirmed that ovarian ultrasonographic characteristics, histological morphology, and serum reproductive hormone levels were consistent with the physiological status of NE and AE gilts. Under the screening thresholds of < 0.05 and |logFC| ≥ 1, we identified 22 lncRNAs that may interact with 21 mRNAs via 50 miRNAs, alongside 39 circRNAs predicted to regulate 26 mRNAs through 72 miRNAs. Functional enrichment analysis indicated that target genes of these differentially expressed transcripts were predominantly enriched in the lysosome pathway, PPAR signaling pathway, chemokine signaling pathway, cholesterol metabolism and NOD-like receptor signaling pathway. Hub molecules including , , , ssc-miR-370, and miR-21-5p were shared in lncRNA/circRNA-miRNA-mRNA regulatory networks; these molecules have been reported to participate in progesterone synthesis, estrus modulation, and endocrine homeostasis. Of particular interest, two non-coding RNAs, MSTRG.1285.1 and novel_circ_056113, were predicted to act as candidate ceRNAs that may sponge ssc-miR-370 and miR-21-5p, which could in turn modulate the expression of estrus-associated mRNAs including , , and . The expression trends of MSTRG.1285.1, novel_circ_056113, miR-370, miR-21-5p, , , and were validated by qRT-PCR, and the quantification results agreed with transcriptome sequencing data. Collectively, this study constructed a predicted ceRNA regulatory network of ovarian transcripts comparing NE and AE gilts and uncovered multiple RNA molecules potentially involved in estrus regulation. These findings offer preliminary theoretical clues for exploring the onset of puberty in gilts. - Source: PubMed
Publication date: 2026/07/30
Lv LingyanZhang JiaqingWu XianhuaLin ChanghuaZhang YangzuMo HongfangLi JiapengLi XunZheng JiamingHu Chuanhuo